Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer

Clinical Cancer Research

Volumn 11, Issue 11, 2005, Pages 4056-4066

  Maxwell, G Larry ^a,b   Chandramouli, G V R ^b   Dainty, Lou ^a   Litzi, Tracy J ^b   Berchuck, Andrew ^c   Barrett, J Carl ^b   Risinger, John I ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; DNA MICROARRAY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIXED MULLERIAN TUMOR; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERUS CANCER;

CLUSTER ANALYSIS; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIXED TUMOR, MULLERIAN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; UTERINE NEOPLASMS;

EID: 20344383528     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2001     Document Type: Article

References (35)

1. American Cancer Society. Cancer facts and figure; 2003.
2. Deligdisch L, Holinka CF. Endometrial carcinoma: two diseases? Cancer Detect Prev 1987;10:237-46, 198.
3. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995;76:2034-40.
4. Kong D, Suzuki A, Zou TT, Sakurada A, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
5. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
6. Risinger JI, Hayes K, Maxwell GL, Barrett C, Berchuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-10.
7. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53: 5100-3.
8. Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A. Microsatellite instability is associated with favorable survival in endometrial carcinomas. Obstet Gynecol 2001;97:417-22.
9. Maxwell GL, Risinger JI, Hayes KA, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res 2000;6:2999-3005.
10. Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-5.
11. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
12. Kohler MF, Carney P, Dodge R, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 1996;175:1246-52.
13. Wada H, Enomoto T, Fujita M, et al. Molecular evidence that most but not all carcinocarcinomas of the uterus are combination tumours. Cancer Res 1997; 57:5379-85.
14. Thompson L, Change B, Barsky SH. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol 1996;20:277-85.
15. Kounelis S, Jones MW, Papadaki H, et al. Carcinosarcoma (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29:82-7.
16. Abeln EC, Smit VTHB, Wessels JW, et al. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mullerian tumours. J Pathol 1997; 183:424-31.
17. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-90.
18. McCluggage WG. Malignant biphasic uterine tumors: carcinosarcomas or metaplastic carcinomas. J Clin Pathol 2002;55:321-5.
19. McCluggage WG, Abdulkadir M, Price JH, et al. Uterine carcinosarcoma in patients receiving tamoxifen: a report of 19 cases. Int J Gynecol Cancer 2000; 37:285-7.
20. Fotiou S, Hatjieleftheriou G, Kyrousis G, et al. Long term tamoxifen treatment: a possible etiological factor in the development of uterine carcinosarcoma: two case reports and review of the literature. Anticancer Res 2000;20:2015-20.
21. Risinger JI, Maxwell GL, Chandramouli GV, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003;63:6-11.
22. Brown T, Mackey K. Analysis of RNA by Northern and slot blot hybridization. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Struhl K, editors. Current protocols in molecular biology. New York: John Wiley & Sons, Inc.; 1997. p. 4.9.2-4.
23. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003;63: 5697-702.
24. Zorn KK, Awtrey CS, Gardner GJ, Barrett JC, Boyd JA, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Gynecol Oncol 2003; 88:abstract 90.
25. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001;107:1491-5.
26. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phophorylase. Hum Pathol 2002;33:213-9.
27. Uotila PJ, Erkkola RU, Klemi PJ. The expression of cyclooxygenase-1 and -2 in proliferate endometrium. Ann Med 2002;34:428-33.
28. Nagamani M, Stuart CA. Specific receptors and growth effects of insulin and insulin-like growth factors in a human cell line derived from mixed mesodermal tumor of the uterus. J Soc Gynecol Investig 1996; 3:281-8.
29. Glondemans T, Prinsen I, Van Unnik JAM, Lips CJM, Otter WD, Sussenbach JS. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res 1990;50:6689-95.
30. Roy RN, Gerulath AH, Cecuttie A, Bhavnani BR. Loss of IGF-II imprinting in endometrial tumors: overexpression in carcinosarcoma. Cancer Lett 2000;153: 67-73.
31. Peinado H, Marin F, Cubillo E, et al. SNAIL and E47 repressors of E-cadherin induce distinctly invasive and angiogenic properties in vivo. J Cell Sci 2004;117: 2827-39.
32. Katoh M, Katoh M. Identification and characterization of human SNAILS (SNAI3) gene in silico. Int J Mol Med 2003;11:383-8.
33. Yoo J, Park S, Kang CS, Kang SJ, Kim BK. Expression of E-cadherin and p53 proteins in human soft tissue sarcomas. Arch Pathol Lab Med 2002;126: 33-8.
34. Halachmi S, DeMarzo AM, Chow NH, et al. Genetic alterations in urinary bladder carcinosarcoma: evidence of a common clonal origin. Eur Urol 2000;37: 350-7.
35. Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 1994;7:98-102.